| Similar Articles |
|---|
 |
The Motley Fool
June 30, 2008
Brian Orelli |
A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug.   |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
Chemistry World
June 10, 2008
James Mitchell Crow |
A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker. |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
The Motley Fool
May 27, 2009
Brian Orelli |
A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
BusinessWeek
October 13, 2003
Arlene Weintraub |
He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug? |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
CRM
February 2003
David Myron |
Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place. |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
The Motley Fool
September 11, 2009
Brian Orelli |
A Congress Full of Headaches And no drug to fix it. Merck's migraine drugs that block the calcitonin gene-related peptide receptor had such potential to treat what ails me and our government servants. That is, until side effects started popping up. |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
Nurse Practitioner
September 2010
Moloney & Cranwell-Bruce |
Pharmacological Management of Migraine Headaches Migraine is one of the top 20 causes of disability worldwide, occurring in 17.6% of women and 5.7% of men |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
AskMen.com
January 6, 2002
Joshua Levine |
Treating Migraines More than 23 million Americans suffer from migraines, and about 38 million have a genetic propensity to develop the condition at some point in their lives. If you have migraines, you know how debilitating they can be, but you don't have to lose hope... |
The Motley Fool
May 15, 2007
Mike Havrilla |
A Heads-Up on TorreyPines The drugmaker's tezampanel for migraines shows promise after some trials. Investors, take note. |
Chemistry World
January 25, 2013
Andrew Turley |
Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million |
American Family Physician
September 1, 2002 |
Tension Headaches What is a tension headache?... What causes tension headaches?... What can I do about my tension headaches?... |
The Motley Fool
October 7, 2009
Jim Mueller |
Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now. |
The Motley Fool
December 29, 2008
Brian Orelli |
Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes. |
The Motley Fool
November 22, 2006
Brian Lawler |
Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news. |
Entrepreneur
November 2005
Don Debelak |
Doctor's Orders Getting the FDA to give your medical invention the thumbs up can be a challenge. Entrepreneurs, follow this prescription for approval. |
IEEE Spectrum
October 2007
Morgen E. Peck |
Researchers Testing New Electric Treatment for Migraines A small DC current through the skull seems to interrupt the headaches and may even prevent them |
American Family Physician
February 15, 2002 |
Migraine Headache in Children and Adolescents Do children get headaches?... What is a migraine headache?... Do many children get migraine headaches?... What causes migraine?... How is migraine diagnosed?... What can help a headache?... How can my child keep from having migraine headaches?... etc. |
American Family Physician
December 1, 2002 |
What Should I Know About Migraines? What are migraines?... How can my doctor tell that my headache is a migraine?... How is migraine headache treated?... What about the headache pain I'm having right now?... What are the "triptans"?... What else can I do?... etc. |
Science News
January 6, 2001 |
Migraine: What a Pain! The Journal of the American Medical Association has developed a Web site that serves as a repository of background information and news of use to migraine victims and their families. Keep up with the latest science by checking abstracts of new journal articles... |
The Motley Fool
June 24, 2011
Arundhati Parmar |
Data on St. Jude Migraine Treatment "Impressive" An effective migraine treatment would be very valuable for St. Jude. |
Chemistry World
June 24, 2015
Matthew Gunther |
Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal. |
The Motley Fool
January 15, 2009
Robert Steyer |
Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy. |
American Family Physician
December 1, 2002
Aukerman et al. |
Management of the Acute Migraine Headache As many as 30 million Americans have migraine headaches. The impact on patients and their families can be tremendous, and treatment of migraines can present diagnostic and therapeutic challenges for family physicians. |
The Motley Fool
September 20, 2007
Brian Lawler |
Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note. |
American Family Physician
October 15, 2000
Sharon Scott Morey |
Practice Guidelines Guidelines on Migraine: Part 2. General Principles of Drug Therapy... |
BusinessWeek
January 24, 2005
Gene G. Marcial |
Curing Spectrum's Headaches? Tiny Spectrum Pharmaceuticals, which has yet to make a dime, looks set to take on Big Pharma. |
Chemistry World
July 29, 2015
Katrina Megget |
Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell. |
Managed Care
May 2004
Dodick & Lipsy |
Advances in Migraine Management: Implications for Managed Care Organizations In response to the expense of new migraine therapies, treatment practices aimed at controlling direct costs are now the norm. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note. |
CIO
December 14, 2010
Kim S. Nash |
How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan. |
BusinessWeek
March 25, 2010
Elizabeth Lopatto |
And Now, Gastric Surgery for Kids Allergan wants to market its Lap-Band implants for younger obese patients, but some doctors are balking |
BusinessWeek
December 25, 2006
Palmeri & Weintraub |
Silicone Goes Subtle Allergan's campaign relies on friendly persuasion. |
American Family Physician
January 1, 2006 |
Medicines to Prevent Migraine Headaches A patient hand-out on the painful condition, its causes, treatment options and prevention recommendations. |
American Family Physician
December 15, 2004 |
Rebound Headaches An informative brochure on triggers for chronic headaches and treatment options. |
American Family Physician
October 15, 2005
Huntington & Yuan |
Topiramate (Topamax) for Migraine Prevention Topiramate is more effective than placebo for migraine prevention. Its effectiveness appears to be similar to that of other antiepileptic drugs and beta blockers. |
American Family Physician
December 15, 2004
Morris Maizels |
The Patient with Daily Headaches Although the condition is challenging, appropriate treatment of patients with chronic daily headaches (CDH) can bring about significant improvement in the patient's quality-of-life. |
Chemistry World
November 27, 2015
Anthony King |
Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes. |
The Motley Fool
January 2, 2004
Dave Marino-Nachison |
Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development. |
American Family Physician
January 1, 2006
MODI Lowder |
Medications for Migraine Prophylaxis Sufficient evidence and consensus exist to recommend propranolol, timolol, amitriptyline, divalproex, sodium valproate, and topiramate as first-line agents for migraine prevention. |
American Family Physician
November 1, 2000
Sharon Scott Morey |
Guidelines on Migraine: Recommendations for Individual Drugs The following is an excerpt of the section in the migraine guidelines that outlines the findings from clinical studies and the specific recommendations for individual drugs... |
